M. Frueh
YOU?
Author Swipe
View article: 155P Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
155P Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14 Open
The use of immune checkpoint inhibitors (ICI) in a neoadjuvant or perioperative treatment concept emerges as a new standard for patients with resectable stage III NSCLC. There are however concerns about patients who cannot undergo definiti…
View article: 12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial
12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial Open
ABC-lung explores the potential synergistic effect of combining atezolizumab and bevacizumab with pemetrexed (ABPem) or carboplatin/paclitaxel (ABCPac) in pts with EGFR-mutant NSCLC, resistant to tyrosine kinase inhibitors (TKIs). ABC-lung…
View article: 1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors Open
View article: 1016O Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC
1016O Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC Open
View article: 1540P Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC)
1540P Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) Open
View article: 970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC
970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC Open
View article: C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer Open
Biomarkers for predicting response to anti-programmed death-1 (PD-1) immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) remain in demand. Since anti-tumor immune activation is a process, early dynamic changes of the acu…
View article: SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial Open
View article: ES09.03 How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost
ES09.03 How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost Open
View article: Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08) Open
View article: Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice
Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice Open
Background: In the randomised Ph III OAK study, atezo (anti–PD-L1) significantly improved survival vs docetaxel, regardless of PD-L1 levels, and was approved by the FDA and EMA as 2L+ tx for advanced NSCLC. Given limited real-world data (R…
View article: Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies
Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies Open
Background: Anti-PD-(L)1 monoclonal antibodies (mAb) have changed the therapeutic landscape in patients with advanced NSCLC, still 35-40% of these patients derive no benefit from anti-PD-(L)1 mAb. Antibiotics alter gut microbiota diversity…
View article: IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC Open
Background: Atezo (anti–PD-L1) + bev + chemo prolonged PFS and OS vs bev + chemo in patients (pts) with 1L nonsquamous NSCLC in the randomized Phase III IMpower150 study. This combination was well tolerated and its safety profile was consi…
View article: Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK Open
View article: 169P: Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
169P: Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study Open
View article: 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC) Open
View article: 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial
143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial Open
View article: Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) Open